TransThera Sciences (Nanjing) (2617 HK)

TransThera Sciences (Nanjing) Inc. is a China-based biopharmaceutical company focused on discovering and developing innovative small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. Its core product, Tinengotinib (TT-00420), is a multi-targeted kinase (MTK) inhibitor in clinical stages for treating relapsed or refractory, drug-resistant solid tumors. The company is headquartered in Nanjing, China, and was founded in 2014.